SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Sodium chloride 0.9% is an isotonic crystalloid solution that increases intravascular volume by replacing extracellular fluid and electrolytes. It does not have a specific molecular target; its primary pharmacological effect is osmotic expansion of the vascular compartment.
| Metabolism | Sodium and chloride ions are distributed throughout extracellular fluid and excreted primarily by the kidneys; no metabolic degradation occurs. |
| Excretion | Primarily renal (>95%). Sodium and chloride ions are freely filtered at the glomerulus and undergo variable tubular reabsorption depending on volume status; excess is excreted unchanged in urine. Fecal and biliary elimination are negligible. |
| Half-life | Not applicable as a conventional drug; sodium and chloride are endogenous electrolytes. The infused ions are distributed and eliminated according to body homeostasis. The plasma half-life of an infused sodium load is approximately 30-60 minutes in euvolemic individuals, but is highly variable based on renal function and volume status. |
| Protein binding | Negligible (<1%). Sodium ions do not significantly bind to plasma proteins. |
| Volume of Distribution | Approximately 0.2-0.3 L/kg (confined largely to extracellular fluid; sodium is primarily extracellular). In clinical contexts, Vd approximates extracellular volume, which is about 0.2 L/kg in lean adults. |
| Bioavailability | Intravenous: 100%. Not administered via other routes; oral bioavailability of sodium chloride is 100% but not used for cardiac output indication. |
| Onset of Action | Intravenous: Immediate upon infusion; plasma volume expansion occurs within minutes. Cardiac output enhancement begins within 1-2 minutes and peaks during infusion. |
| Duration of Action | Intravenous: Plasma volume expansion persists for 30-60 minutes after infusion cessation, depending on renal elimination rate. Hemodynamic effects on cardiac output last 15-30 minutes post-infusion. |
| Molecular Weight | 58.44 |
Intravenous injection of 10 mL of 0.9% sodium chloride solution for cardiac output determination via thermodilution, repeated as needed every 3-5 minutes for up to 3 injections per measurement set.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR-based renal impairment as this is a diagnostic agent without systemic absorption or pharmacologic effect. |
| Liver impairment | No dose adjustment required for Child-Pugh class A, B, or C hepatic impairment as this is a diagnostic agent without systemic absorption or pharmacologic effect. |
| Pediatric use | For children, 0.15 mL/kg per injection (maximum 10 mL) of 0.9% sodium chloride solution, administered intravenously for cardiac output determination via thermodilution, repeated as needed every 3-5 minutes for up to 3 injections per measurement set. |
| Geriatric use | No specific dose adjustment required; administer same adult dose (10 mL intravenous injection) with caution for volume status in elderly patients with renal or cardiac impairment. |
| 1st trimester | Sodium chloride 0.9% is considered safe for use during the first trimester when administered as a volume expander or for cardiac output measurement. No known teratogenic risk. |
| 2nd trimester | Safe for use; no evidence of fetal harm. Standard precautions for fluid overload and electrolyte imbalance apply. |
| 3rd trimester | Safe but monitor for fluid overload and electrolyte disturbances, especially in cases of preeclampsia or compromised renal function. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Sodium and chloride ions freely cross the placenta via passive diffusion and active transport. No significant retention or accumulation. |
| Breastfeeding | Sodium chloride 0.9% is compatible with breastfeeding. It is a normal constituent of breast milk and no special precautions are needed. |
| Lactation Rating | Safe |
| Teratogenic Risk | Sodium chloride 0.9% is a physiologic solution; no teratogenic effects are known. During all trimesters, use is considered safe when administered as indicated. No fetal risk has been reported. |
| Fetal Monitoring | Monitor serum electrolytes, fluid balance, and signs of fluid overload (e.g., edema, pulmonary congestion) in both mother and fetus. Cardiac output monitoring as indicated for the procedure. |
| Fertility Effects | No known effects on fertility. Sodium chloride 0.9% is not associated with reproductive toxicity. |
■ FDA Black Box Warning
None.
| Common Effects | fluid replacement |
| Serious Effects |
HypernatremiaFluid overloadSevere electrolyte imbalance
| Precautions | Risk of fluid overload, especially in patients with heart failure, renal impairment, or pre-existing edema, Hypernatremia may occur with excessive administration, Monitor serum electrolytes, fluid status, and central venous pressure during prolonged use, Use with caution in patients with hypertension, congestive heart failure, or impaired renal function |
| Food/Dietary | No known food interactions. Maintain standard fasting guidelines (e.g., NPO 6-8 hours) prior to cardiac output measurement if required by institutional protocol. |
| Clinical Pearls | Use 0.9% sodium chloride for thermodilution cardiac output measurement; inject 10 mL rapidly via proximal injectate port. Ensure temperature of injectate is 0-5°C for accurate readings. Avoid air bubbles in syringe to prevent erroneous measurements. Verify central line placement before injection. |
| Patient Advice | This solution is sterile and used to measure how well your heart is pumping blood. · You may feel a cold sensation when the solution is injected into your central line. · Inform your nurse if you experience chest pain, shortness of breath, or dizziness during the procedure. · Do not consume food or drink immediately before the procedure unless instructed otherwise. |
Loading safety data…